In-vivo Gene Therapy Rare Diseases Market Size, Scope, Forecast Report 2026 to 2035

What is In-vivo Gene Therapy Rare Diseases Market Size?

Global In-vivo Gene Therapy Rare Diseases Market Size is valued at USD 9.10 Bn in 2025 and is predicted to reach USD 47.04 Bn by the year 2035 at a 18.1% CAGR during the forecast period for 2026 to 2035.

In-vivo Gene Therapy Rare Diseases Market Size, Share & Trends Analysis Distribution by Delivery Vector (Lipid Nanoparticle (LNP), Lentiviral, AAV-Based, and Non-Viral), Therapy Stage (Approved Products, Phase II Clinical, and Phase III Clinical), Disease Area (Metabolic Disorders, Lysosomal Storage Disorders, Cardiovascular Rare Diseases, Neuromuscular Diseases, and Ocular Disorders), and Segment Forecasts, 2026 to 2035.

A therapeutic strategy known as "in-vivo gene therapy" for uncommon diseases involves introducing genetic material directly into a patient's body in order to treat or possibly cure illnesses brought on by defective or absent genes. It uses vectors such aa lentiviruses, adeno-associated viruses (AAV), or non-viral delivery vehicles to deliver therapeutic genes directly into target tissues or organs. It is a revolutionary field in the treatment of rare diseases and precision medicine since it provides benefits including tailored treatment, less need for recurrent interventions, and the opportunity to address diseases at their core cause. The rapid expansion of regulatory approvals, significant clinical triumphs, and an unparalleled inflow of venture financing and big-pharma alliances aimed at orphan indications are key factors driving the in-vivo gene therapy rare diseases market's growth.

The in-vivo gene therapy rare diseases market is being driven by the increasing frequency of uncommon genetic disorders and developments in genetic medicine. These therapies can cure diseases at their source by directly delivering therapeutic genes into the patient's body. The adoption and investment in this field are being accelerated by growing success in treating ailments such as hemophilia, metabolic diseases, inherited retinal impairments, and spinal muscular atrophy. Further driving market expansion are the growing emphasis on precision medicine, favorable regulatory incentives for orphan pharmaceuticals, and growing research into viral and non-viral delivery routes. Moreover, the in-vivo gene therapy rare diseases market is growing because biotechnology and pharmaceutical companies are becoming more involved in the development of novel gene treatments.

In addition, the in-vivo gene therapy rare diseases market is anticipated to be influenced by ongoing advancements in vector engineering, targeted delivery systems, and gene editing technologies that are enhancing therapeutic efficacy and safety. The demand for these therapies is also being supported by an increasing focus on long-term curative treatments rather than symptom management. New growth prospects are also anticipated as a result of increased funding for rare illness research and regulatory backing for cutting-edge treatments. Additionally, the in-vivo gene therapy rare diseases market is moving toward next-generation treatments intended for better patient outcomes and a wider range of disease applications. However, the in-vivo gene therapy rare diseases market faces substantial obstacles due to reimbursement and regulatory barriers.

Competitive Landscape

Which are the Leading Players in In-vivo Gene Therapy Rare Diseases Market?

• Ultragenyx Pharmaceutical
• Novartis (AveXis)
• Rocket Pharmaceuticals
• Ascendis Pharma
• Sarepta Therapeutics
• Intellia Therapeutics
• REGENXBIO
• CSL Behring
• Pfizer
• BioMarin Pharmaceutical
• uniQure
• Spark Therapeutics (Roche)

Market Dynamics

Driver

Growing Incidence of Rare Genetic Disorders

The in-vivo gene therapy rare diseases market is mostly driven by the growing incidence of rare genetic disorders as well as improvements in gene delivery methods. These treatments are very appealing for illnesses with few therapy options because they can target the underlying genetic etiology of diseases rather than just treating their symptoms. The healthcare professionals and investors are more confident due to the growing success of treating conditions, including hemophilia, spinal muscular atrophy, and inherited retinal diseases. Additionally, the in-vivo gene therapy rare diseases market growth is being accelerated by increasing clinical trial activity, significant investments from pharmaceutical and biotechnology businesses, and favorable regulatory incentives for orphan medications. The safety, effectiveness, and long-term therapeutic results of treatment are also being improved by advancements in gene editing and viral vector technology.

Restrain/Challenge

High Expense of Creating and Delivering In-vivo Gene Therapy

The in-vivo gene therapy rare diseases market is severely constrained by the high expense of creating and delivering in-vivo gene treatments. The high therapeutic costs associated with these medicines can restrict patient access because they frequently call for intricate research, sophisticated manufacturing techniques, and specialized delivery systems. Furthermore, lengthy approval processes and strict regulations might raise development costs and postpone product commercialization. The growth is also hampered by safety concerns about immunological reactions, off-target consequences, and uncertainty about the long-term stability of therapy outcomes. The in-vivo gene therapy rare diseases market penetration is hampered by inadequate healthcare infrastructure in some areas and limited reimbursement frameworks. 

Lipid Nanoparticle (LNP) Segment is Expected to Drive the In-vivo Gene Therapy Rare Diseases Market

The Lipid Nanoparticle (LNP) category held the largest share in the In-vivo Gene Therapy Rare Diseases market in 2025 driven by the growing need for safe, effective non-viral delivery methods for genetic medications. The capacity of LNPs to deliver nucleic acids such as mRNA, siRNA, and gene-editing components directly into target cells while lowering some of the drawbacks of viral vectors, such as immunogenicity and manufacturing complexity, has drawn a lot of attention. Additionally, the growth in this market is also being supported by increased applications of RNA-based treatments, growing research in uncommon genetic illnesses, and growing use of precision medicine. The innovation is also being accelerated by improvements in targeting capabilities, advances in LNP formulation technologies, and growing investments from pharmaceutical and biotechnology businesses.

Metabolic Disorders Segment is Growing at the Highest Rate in the In-vivo Gene Therapy Rare Diseases Market

In 2025, the Metabolic Disorders category dominated the In-vivo Gene Therapy Rare Diseases market due to the growing emphasis on addressing the genetic basis of hereditary metabolic disorders. Due to the limited efficacy of traditional treatments, disorders include lysosomal storage diseases, phenylketonuria, and other ailments related to enzyme deficiencies are driving up demand for sophisticated gene therapies. In this field, in-vivo gene therapy is becoming more and more popular due to its capacity to transfer genes directly and fix underlying mutations for long-term therapeutic advantages. Moreover, the growing clinical pipelines, increasing investments in treatments for uncommon metabolic illnesses, and more research activities are all contributing to the segment's expansion.

Why North America Led the In-vivo Gene Therapy Rare Diseases Market?

The In-vivo Gene Therapy Rare Diseases market was dominated by North America region in 2025 fueled by significant expenditures in genetic research, a robust presence of top pharmaceutical and biotechnology businesses, and an advanced healthcare infrastructure. The high rates of diagnosed rare diseases, growing uptake of novel treatments, and supporting regulatory frameworks—such as incentives for orphan drugs and accelerated approval processes—all benefit the region.

Additionally, the in-vivo gene therapy rare diseases market is expanding due to increased clinical trial activity, robust financing support from public and private institutions, and growing partnerships between academic institutions and business leaders. Because of its strong gene therapy pipeline and early acceptance of cutting-edge medicines, the United States dominates the regional market.

In-vivo Gene Therapy Rare Diseases Market Report Scope: